Acarix announce final outcome in oversubscribed rights issue


Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of
86,156,738 shares with preferential rights for the Company's existing shareholders, which was
resolved by the extra general meeting on 11 August 2020 (the "Rights Issue"). Acarix today
announces the final outcome of the Rights Issue, which shows, in line with what was
communicated 9 September 2020, that the Rights Issue has been oversubscribed.




About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit